Milanova Tsveta

Chief Commercial OfficerAGIOS PHARMACEUTICALS, INC. (AGIO) · full profile →Form 4 · filed Mar 3, 2026
Net Selling
Open-Market Buys
$0
Open-Market Sells
$83K
Net Open-Market Flow
-$83K
Transactions
8
4 non-derivative · 4 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Mar 2, 2026Option exercise(M)4K$043K
Mar 2, 2026Sell(S)1K$28.96$34K42K
Mar 2, 2026Option exercise(M)6K$040K
Mar 2, 2026Sell(S)2K$28.96$49K39K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Mar 2, 2026Option exercise(M)4K$08K
Mar 2, 2026Option exercise(M)6K$06K
Mar 1, 2026Grant(A)52K$052K
Mar 1, 2026Grant(A)14K$014K

Transaction Codes

M
Option exercise / conversion
S
Open-market sale
A
Grant / award

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001439222-26-000036) within minutes of acceptance. Every field above traces to the original document. Verify it directly: